Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.
Gowrie Balasubramaniam, Mike Almond, Patrick Harnett et al.
✦ AI-curated · Sources linked
In 30 seconds
The ASGARD study was a feasibility randomized controlled trial comparing anakinra to intramuscular methylprednisolone acetate for treating gout flares in patients with chronic kidney disease. Conducted across four UK centers, the trial enrolled 21 participants, with a mean pain reduction of 46.8 mm on a 100 mm visual analogue scale after 7 days. The study did not meet its overall recruitment goals.
Key findings
- 21 participants were randomized, with 17 receiving the allocated treatment.
- Mean pain reduction after 7 days was 46.8 mm on the visual analogue scale.
- The trial met procedural feasibility with ≥70% of eligible patients recruited.
- Qualitative feedback indicated high questionnaire burden and treatment delays.
Why it matters
Understanding the feasibility of using anakinra for gout flares in patients with chronic kidney disease can inform future research and treatment strategies, particularly in a population at risk for complications.
What to keep in mind
The trial did not meet its overall recruitment goals, which limits the generalizability of the findings.